Psychedelic-Assisted Therapies

A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provided preliminary data on the treatment’s safety and efficacy, reported Marijuana Moment’s Ben Adlin. Published by the Journal of the American...

The latest San Francisco 49ers and Philadelphia Eagles match (42-19) brought on additional highlights on players’ charity choice for the NFL “My Cleats, My Cause” campaign. This week's NFL game between the San Francisco 49ers and the Philadelphia Eagles brought...

Defense Dept. Funds Ketamine Study For PTSD Treatment  A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos...

Ontario-based Canadian psychedelics company Braxia Scientific Corp. (OTC Pink: BRAXF) filed its interim financial statements and management discussion for the three and six months ended Sept. 30, 2023.  Numbers show: Cash of $524,454 (CA$709,681) by Sept. 30, vs. $636,483 by...

Supermodel Chrissy Teigen recently celebrated her 38th birthday surrounded by her loved ones and ketamine therapy. Via her Instagram account, she said the psychedelic session made her see “space and time” as well as baby Jack “and some weird penguins,”...

Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a relatively small trial, outcomes for the novel psychedelic are so far showing strong treatment efficacy...

Canada-based all-mushroom producer Red Light Holland Corp. (OTCQB: TRUFF) filed its quarterly financial statements and management discussion and analysis for the three and six months ended Sept. 30, 2023. Numbers show: Cash and cash equivalents of $12.0 million (CA$16.4 million) by Sept. 30...

Psychedelics biotech Seelos Therapeutics (NASDAQ: SEEL) announced the pricing of a new underwritten public offering for an estimated $5.5 million in gross proceeds. The offering is expected to close on or about Dec. 1, 2023. On Tuesday, Seelos shares’ closing price was at $2.35, and Wednesday...

A Department of Defense (DOD) Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos Therapeutics (...

Norwegian Survey Some 770 individuals over 18 completed a survey put together by researchers at Østfold Hospital Trust and the University of Oslo aiming to map what psychedelics users experience.  Though these substances are still illegal in Norway, study author psychiatrist...

Australian Coalition Calls For Psychedelic Rules Review Following roughly five months since the country’s Therapeutic Goods Administration (TGA) officially enabled the prescription of MDMA and psilocybin-assisted therapies for certain mental health conditions, a new coalition of healthcare...

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan Vivek Ramaswamy, who famously said he did not approve of Ohio’s cannabis initiative last week despite expressing support for federal legalization, is now saying that if elected he will...

Clearmind Medicine Inc. (NASDAQ: CMND) is set to conduct a 1-for-30 reverse share split of its issued and outstanding ordinary shares, no par value, effective starting Nov. 28, 2023.  See Also: Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering...

Johns Hopkins University’s new congressional briefings series chapter, “What’s next for psychedelics,” covered a wide range of topics including clinical research specificities, therapists' training, policy hurdles, potential economic impact and necessary safeguards. The...

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD). Details On Trials Compass...